Introduction
Acta Haematologica Polonica safety profile, as indicated by lower hepatic and renal toxicity [16] .
Recent studies have demonstrated the involvement of drug transport proteins in the in vivo absorption, cellular distribution, and elimination of HU [17] . HU has long been utilized in both human and veterinary medicine. Although it was first synthesized in 1869, trials for testing the safety of this drug in humans started only after a century [18] . 
HbF induction
HU has been in use for the treatment of SCD over many years. The main rationale behind the usage of HU for the treatment of SCD is its ability to induce HbF [19] . The possible cellular and vascular effects of HU are depicted in figure 3 . Several lines of evidence suggest that HU elicits HbF induction and offers clinical benefits to SCD patients through a wide range of possible mechanisms [20] . The precise mechanism of HbF induction by HU is not fully known; however, it is mediated mainly by the redox inactivation of a tyrosyl radical on the enzyme ribonucleotide reductase [21] .
The absorption, distribution, and excretion of HU vary greatly among individuals. HU causes intermittent cytotoxic suppression of erythroid progenitors and cell stress signaling, which leads to recruitment of erythroid progenitors with increased HbF levels [22, 23, 24] . HU is also involved in free radical formation, iron chelation, activation of soluble guanylyl cyclase, and direct nitric oxide (NO) production [25] . HU shows cytotoxic effects and reduces the absolute numbers of neutrophils, reticulocytes, and platelets in the bone marrow. Reduction of platelets reduces inflammation, while reduction of neutrophils and reticulocytes reduces the surface expression of adhesion receptors and alters the adhesion of RBCs to the endothelium [26] .
NO production
NO plays a critical role as a molecular mediator of a variety of physiological processes, including vascular tone regulation and neurotransmission. NO synthesis results from the action of NO synthetase (NOS) on nonessential amino acids, such as arginine, and molecular oxygen [27] . Further, this free-radical gas molecule is produced in vitro by the oxidation HU by heme groups [28] . Significant 
Modulation of RBC -endothelial cell interactions

Proof of efficacy
In adults, HU increases the amount of total hemoglobin as well as HbF and thereby reduces acute complications, in terms of both number and severity [44] . After studying the safety and efficacy of HU therapy in patients with SCA, HU has been approved for the treatment of adult sickle cell patients [45] . Furthermore, prolonged HU therapy in infants with SCA showed sustained hematologic benefits, reduced acute coronary syndrome (ACS) events, improved growth, and preserved organ function. The Hydroxyurea Safety and Organ Toxicity (HUSOFT) extension study revealed that patients who continued the HU therapy showed better spleen function than expected and improved growth rates [46] . Regeneration of splenic function was also demonstrated in adult patients with severe hemoglobin SC disease [47] . Many studies used level of HbF induction as a predictor of HU therapy. A substantial increase in serum erythropoietin levels has been noted, 2-3 weeks after initiation of HU treatment in SCA and HbS/beta-thalassemia patients [48] .
Attenuation of organ dysfunction
Although there was a great improvement in survival for children with SCD, the failure of two or more organ systems is associated with morbidity in SCD. Sickle cell patients develop splenic dysfunction early (4-6 months of age) in the course of their disease [49] . This raises the possibility that HU therapy might be able to exert a significant disease-modifying effect in young children with SCD. The efficacy of HU in preventing acute complications and organ damage in children with SCA was assessed in a Phase III multicenter randomized 
SCD management with HU
Although there is no cure for SCD, the oral chemotherapeutic drug HU is used for ameliorating the disease and improving life expectancy for most patients. The randomized BABY HUG trial has demonstrated that HU significantly reduces the incidence of VOC and dactylitis in young children [50] . There are no universally agreed indications for the initiation HU therapy in SCD patients. However, team members must review the medical history and discuss the recommendation openly with patients and families before initiating HU therapy. The initial dosage of HU for adults is 15 mg/kg/day; the dose may be reduced further to 10 mg/kg/day in patients with impaired renal function.
The HUSOFT and BABY HUG trials demonstrated that 20 mg/kg/ day improved hematologic parameters, provided substantial clinical benefits, and had an excellent safety profile [58, 59] . Several clinical trials have reported good clinical outcomes by using a "clinically effective dose" of 15-20 mg/kg/day [60, 61] . The positive effects of HU can be seen within weeks of commencing therapy [62] . The primary toxicity observed was neutropenia. When adjusting dosage, continuous monitoring of complete blood count (CBC) and absolute reticulocyte count (ARC) should be adopted at least every 4 weeks [63] .
Further study is needed to evaluate the long-term treatment effects on growth and development, as well as on kidney, lung, and central nervous system function. A randomized, placebo-controlled trial in adults did not demonstrate a significant improvement in the time to resolution of VOC [64] . Adults with SCD should be evaluated for known stroke risk factors and managed according to the 2011 American Heart Association/American Stroke Association (AHA/ ASA) primary stroke prevention guidelines. HU or bone marrow transplantation is the only option for children at high risk for stroke in whom RBC transfusion is contraindicated [65] . HU therapy decreases TCD flow velocities [66] , and this decrease may be associated with decreased turbulent flow and the consequent endothelial damage around the stenosis. An open-label pilot study revealed that long-term HU therapy improved cerebral oxygen saturation [67] . However, this improved oxygen saturation may raise the threshold for infarction by augmenting the oxygen reservoir [68] . The BABY HUG trial reported that cerebrovascular events occur only in about 10% of SCD children taking HU therapy [50] . Hence, HU seems to be a highly useful alternative and is relatively free of serious side effects.
Adverse effects of HU
Results of the BABY HUG Trial revealed that HU has an excellent safety profile, and side effects of HU therapy in young patients with SCD are usually low. As HU causes severe myelosuppression, patients should be monitored during treatment for cytopenias very carefully, particularly while seeking the maximum tolerated dose [69] . In children receiving HU therapy, kidney and liver toxicity was not statistically significant compared to the placebo group [70] . Further, these groups showed similar rates of cytopenia, including severe neutropenia, thrombocytopenia, and anemia with reticulocytopenia. Furthermore, a MSH study reported hair loss, skin rash, gastrointestinal disturbance, and fever in the HU-treated group, but it was not statistically significant compared to the placebo group [71] . Cutaneous side effects include nail hyperpigmentation, as well as increased skin pigmentation on the palms and soles [72] . Further, leg ulceration has been reported as a rare cutaneous manifestation of HU therapy in a few studies [73, 74, 75] . Assessment of renal function and the pharmacokinetics of HU indicate that the renal impairment results in increased systemic exposure and decreased urinary recovery of the drug [16] . Some patients receiving HU therapy showed mild albuminuria, with an increase in white cells and granular casts, as well as occasional red cells, in the urine [76] . However, the BABY HUG trial demonstrated that HU is associated with better urine-concentrating ability and less renal enlargement, in addition to improvement in overall renal function [58] . Studies in animal models revealed that HU therapy inhibits spermatogenesis and results in hypogonadism [77] . Semen analysis of SCD patients demonstrated impaired sperm count, motility, and morphology while taking HU therapy [78] .
There is increasing concern about the occurrence of malignancy or myelodysplasia in patients with SCD on HU therapy [79, 80] .
Several scattered reports document the malignancy that occurs in both children and adults with SCD but do not provide complete information on the incidence of various cancer types [81, 82, 83, 84, 85] . Furthermore, a multicenter study that assessed the risks and benefits for up to 9 years of HU treatment did not show development of secondary leukemia in adults [86] . This indicates that the carcinogenic potential of HU in clinical settings is much less influential. HU is a potent teratogen in all animal species yet tested and thus qualifies as a universal teratogen [87] . The teratogenicity of HU was demonstrated by documenting various anomalies in the central nervous system, palate, as well as the genitourinary, cardiac, ocular, and multiple skeletal systems [88, 89, 90] . As very large doses (> 250 mg/kg per 24 hours) have been reported as teratogenic, the safety of HU therapy in pregnancy remains unclear. Outcome of pregnancy with HU treatment in 31 cases revealed that the there was no major malformation in the case series with exposure to HU [91] . However, this study documented significant rates of intrauterine growth retardation (IUGR), fetal death, and prematurity; hence, careful follow-ups with physical, biological, and sonographic examination are warranted. A follow-up study of the original MSH trial revealed that exposure of the fetus to HU does not cause teratogenic changes [92] . 
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